Evidence map›Paper›PMID 32946151›Full record

ArticleEuropean journal of heart failure2021

Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a/V2 receptor antagonist in experimental heart failure.

Thomas Mondritzki, Thuy Anh Mai, Julia Vogel, Elisabeth Pook, Pierre Wasnaire, Carsten Schmeck, Jörg Hüser, Wilfried Dinh, Hubert Truebel, Peter Kolkhof

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. New and future heart failure drugs.Nature cardiovascular research · 2024
    Review
  4. Review
  5. Review
  6. Advanced heart failure: from definitions to therapeutic options.European heart journal supplements : journal of the European Society of Cardiology · 2023
    Article
  7. Review
  8. Review
  9. Review
  10. Updates and Perspectives on Aquaporin-2 and Water Balance Disorders.International journal of molecular sciences · 2021
    Review
  11. Conformational selection of vasopressin upon VComputational and structural biotechnology journal · 2021
    Article
  12. New Targets in Heart Failure Drug Therapy.Frontiers in cardiovascular medicine · 2021
    Review
  13. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Thomas MondritzkiBayer AG, Wuppertal, Germany.
Thuy Anh MaiUniversity of Witten/Herdecke, Witten, Germany.
Julia VogelUniversity of Witten/Herdecke, Witten, Germany.
Elisabeth PookBayer AG, Wuppertal, Germany.
Pierre WasnaireBayer AG, Wuppertal, Germany.
Carsten SchmeckBayer AG, Wuppertal, Germany.
Jörg HüserBayer AG, Wuppertal, Germany.
Wilfried DinhBayer AG, Wuppertal, Germany.
Hubert TruebelBayer AG, Wuppertal, Germany.
Peter KolkhofBayer AG, Wuppertal, Germany.
Bayer (Germany) · DEWitten/Herdecke University · DEUniversity of Duisburg-Essen · DE

Funding

Bayer AG
6 · The paper itself

Abstract

aimsArginine vasopressin (AVP) mediates deleterious effects via vascular V1a and renal V2 receptors in heart failure (HF). Despite positive short-term decongestive effects in phase II HF studies, selective V2 receptor antagonism has shown no long-term mortality benefit, potentially related to unopposed V1a receptor activation. We compared the novel dual V1a/V2 receptor antagonist pecavaptan with the selective V2 receptor antagonist tolvaptan in pre-clinical HF models. METHODS AND

resultsIn vitro IC50 determination in recombinant cell lines revealed similar receptor selectivity profiles (V2:V1a) of tolvaptan and pecavaptan for human and dog AVP receptors, respectively. Two canine models were used to compare haemodynamic and aquaretic effects: (i) anaesthetised dogs with tachypacing-induced HF, and (ii) conscious telemetric dogs with a non-invasive cardiac output (CO) monitor. Tolvaptan and pecavaptan exhibited no differences in urinary output. In HF dogs, pecavaptan counteracted the AVP-induced increase in afterload and decrease in CO (pecavaptan: 1.83 ± 0.31 L/min; vs. tolvaptan: 1.46 ± 0.07 L/min, P < 0.05). In conscious telemetric animals, pecavaptan led to a significant increase in CO (+0.26 ± 0.17 L/min, P = 0.0086 vs. placebo), in cardiac index (+0.58 ± 0.39 L/min/m

conclusionsSimultaneous blockade of vascular V1a and renal V2 receptors efficiently induces aquaresis and counteracts AVP-mediated haemodynamic aggravation in HF models. Dual V1a/V2 antagonism may lead to improved outcomes in HF.

Indexed as

Heart FailureReceptors, VasopressinAnimalsAntidiuretic Hormone Receptor AntagonistsCardiac OutputDogsVasopressinsAntidiuretic Hormone Receptor AntagonistsReceptors, VasopressinVasopressinsAnimal modelHeart failurePecavaptanV1a receptorV2 receptorVasopressin antagonist

Identifiers

PMID32946151
PMCPMC8359415
OpenAlexW3087197490

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.